

Beyond the Pipeline: Advancing the Future of Health

Alejandra López Barquero
Medical Director Central America & Caribe

August 2026


Health
is everything

We discover, develop, and deliver transformative medicines to those who need them most





We work to understand the biology of disease with the goal of transforming medicine in areas where unmet medical need remains high

We focus our innovation where patient need is greatest and scientific opportunity is deepest, transforming millions of lives as we work to **prevent, treat, and one day cure** some of the world's most devastating diseases.

Advances in science and technology are shaping the future of medicine

- Precision Medicine
- New modalities and platforms
- AI Drug Discovery
- GenAI
- Data Science
- Digital twin
- Digital Health

Innovating with purpose to lead the future of medicine

Areas of Focus



Oncology

Eliminating cancer by offering transformative therapeutic and diagnostic solutions

Immunology

Boosting Remission in Patients with Immune Diseases

Neuroscience

Leading the Precision Neuroscience Revolution

Enabling innovation

Advancing the next wave of modalities with targeted investments, strategic alliances and collaboration

Scale priority AI and data approaches to improve productivity and drive simplification, including AI-powered drug discovery

Innovation that redefines treatment standards needs science, investment and continuity

13,000+

Global scientists and researchers

$14.7B

Invested in research and development (R&D) in 2025[1]

70+

New therapies and product expansions projected towards 2030

1 https://s203.q4cdn.com/636242992/files/doc_financials/2025/q4/JNJ-Earnings-Presentation-Q4-2025-Final.pdf

Global Development in the R+D Chain



Every decision we make happens at the end of a long and highly demanding process. Evidence and system vision required

Reclaiming living by revolutionizing treatment, starting now

Our vision

Restore health for all patients with immune diseases

Our mission

Driven by a relentless dissatisfaction with the status quo, we are redefining treatments for immune diseases by delivering transformational and accessible therapies and regimens to patients with autoimmune disease

Our leadership approach

- Translate immune insights to treatments
- Tirelessly focus on patient unmet needs
- Achieve remission

From Someday…

Hijacked lives with chronic disease state treatments
only capable of improving symptoms

We focus on patients at every phase of life

To Everyday…

Reclaimed life enabled by revolutionary treatments
restoring health everyday

Focus areas in immunology



Our Focus

Our focus on understanding disease at the molecular level is key to the discovery of new targets that drive inflammation and autoimmune processes, and our early work on understanding disease triggers may enable entirely
new approaches to treating and potentially preventing disease

Autoantibody



Rheumatology



Immunodermatology

Respiratory

Gastroenterology

Our bold vision: Restore health for all patients with immune diseases

Our Mission in Immunology

Driven by a relentless dissatisfaction with the status quo, our mission is to redefine treatments for immune diseases by delivering transformational and accessible therapies and regimens to patients with autoimmune disease.

Our Legacy in Immunology

INFLIXIMAB	GOLIMUMAB	USTEKINUMAB	GOLIMUMAB For infusion	GUSELKUMAB	NIPOCALIMAB	**Icotrokinra (JNJ-2113)**
1998	2009	2009	2013	2017	2025	**2026**
1st US approval						

Johnson&Johnson

Johnson&Johnson
Innovative Medicine

Immunology Pipeline

Focus on Gastroenterology

Guselkumab IBD extends beyond registrational programs[1-2]



Novel translational data clarify the **mechanistic aspects** of GUS tissue effects in QUASAR in UC and GALAXI in CD

- Resolution of IL-23 pathway inflammation
- Wound healing
- Fibroblast reduction

FUZION

A Phase 3 Study to Evaluate the Efficacy and Safety of GUS with a Placebo arm in Adult Patients with **Fistulizing, Perianal Crohn's Disease**

- Highly refractory population
- Limited therapeutic options

A Phase 3 Study to Evaluate the **Transmural Healing** and Disease Modifying Effect of GUS in Crohn's Disease Patients

- Investigates deeper than mucosal surface to evaluate resolution across full bowel wall
- Novel imaging modalities

Post-launch studies on GUS will answer questions in the **real-world setting** including

- Effectiveness
- Patient preference
- Quality of life
- Healthcare resource utilization
- Healthcare cost

FUZION study design | REASON study design

CD: Crohn's disease; GUS: guselkumab; IBD: inflammatory bowel disease; IL: interleukin; UC: ulcerative colitis.
1.Clinical trials.org - https://clinicaltrials.gov/study/NCT06408935?term=NCT06408935&viewType=Card&rank=1 . 2. Clinical Trials.org - https://clinicaltrials.gov/study/NCT05347095


We create new and innovative treatments to change the future of health.